NASDAQ:PSTXPoseida Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Poseida Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $12.90 -0.18 (-1.38 %) (As of 08/5/2020 04:00 PM ET) Add Compare Share Today's Range$12.76Now: $12.90▼$13.9950-Day Range N/A52-Week Range$11.35Now: $12.90▼$17.62Volume518,710 shsAverage Volume569,801 shsMarket Capitalization$797.43 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsInsider TradesHeadlinesSocial Media Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing a pipeline of solutions for the treatment of hematological malignancies and solid tumors, as well as vivo programs for liver-directed gene therapies for rare diseases. In addition, it offers CAR-T therapies for the treatment for cancer. Further, it offers gene therapies for rare and life-threatening diseases, including Ornithine transcarbamylase (OTC) deficiency and methylmalonic acidemia (MMA), and genetic liver diseases. The company was founded in 2014 and is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Poseida Therapeutics. Previous Next 0.0 Community Rank Outperform VotesPoseida Therapeutics has received 4 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPoseida Therapeutics has received 0 “underperform” votes. (Add your “underperform” vote.)MarketBeat's community ratings are surveys of what our community members think about Poseida Therapeutics and other stocks. Vote “Outperform” if you believe PSTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PSTX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldPoseida Therapeutics does not currently pay a dividend.Dividend GrowthPoseida Therapeutics does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Poseida Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $160,000.00 in company stock and sold $0.00 in company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.60 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PSTX Previous Symbol CUSIPN/A CIKN/A Webwww.poseida.com Phone858-779-3100Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees149 Outstanding Shares61,816,000Market Cap$797.43 million Next Earnings DateN/A OptionableNot Optionable $12.90 -0.18 (-1.38 %) (As of 08/5/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive PSTX News and Ratings via Email Sign-up to receive the latest news and ratings for PSTX and its competitors with MarketBeat's FREE daily newsletter. Poseida Therapeutics (NASDAQ:PSTX) Frequently Asked Questions Has Poseida Therapeutics been receiving favorable news coverage? Headlines about PSTX stock have been trending neutral this week, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Poseida Therapeutics earned a news impact score of 0.2 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news about Poseida Therapeutics. Who are some of Poseida Therapeutics' key competitors? Some companies that are related to Poseida Therapeutics include Sorrento Therapeutics (SRNE), Twist Bioscience (TWST), Fate Therapeutics (FATE), Denali Therapeutics (DNLI), Immunovant (IMVT), SpringWorks Therapeutics (SWTX), Mesoblast (MESO), Editas Medicine (EDIT), Legend Biotech (PCVX), Sangamo Therapeutics (SGMO), Adverum Biotechnologies (ADVM), NanoString Technologies (NSTG), Bill.com (RVMD), Forma Therapeutics (FMTX) and Coherus Biosciences (CHRS). View all competitors. Who are Poseida Therapeutics' key executives? Poseida Therapeutics' management team includes the following people: Dr. Eric M. Ostertag, CEO, Sec. & Director (Age 47, Pay $703.16k)Mr. Kerry D. Ingalls, Chief Operating Officer (Age 58, Pay $384.98k)Dr. Matthew A. Spear, Chief Medical Officer (Age 53, Pay $597.94k)Mr. Mark J. Gergen, Pres, Chief Bus. Officer & Director (Age 57)Ms. Johanna M. Mylet C.P.A., Sr. VP of Fin. (Age 33) When did Poseida Therapeutics IPO? (PSTX) raised $150 million in an initial public offering on Friday, July 10th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. BofA Securities, Piper Sandler and William Blair served as the underwriters for the IPO. What is Poseida Therapeutics' stock symbol? Poseida Therapeutics trades on the NASDAQ under the ticker symbol "PSTX." When does Poseida Therapeutics' quiet period expire? Poseida Therapeutics' quiet period expires on Wednesday, August 19th. Poseida Therapeutics had issued 14,000,000 shares in its initial public offering on July 10th. The total size of the offering was $224,000,000 based on an initial share price of $16.00. During Poseida Therapeutics' quiet period, insiders and underwriters involved in the IPO are prevented from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company. How do I buy shares of Poseida Therapeutics? Shares of PSTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Poseida Therapeutics' stock price today? One share of PSTX stock can currently be purchased for approximately $12.90. How big of a company is Poseida Therapeutics? Poseida Therapeutics has a market capitalization of $797.43 million. Poseida Therapeutics employs 149 workers across the globe. What is Poseida Therapeutics' official website? The official website for Poseida Therapeutics is www.poseida.com. How can I contact Poseida Therapeutics? Poseida Therapeutics' mailing address is 9390 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The company can be reached via phone at 858-779-3100. This page was last updated on 8/5/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
